1. Home
  2. IMUX vs VANI Comparison

IMUX vs VANI Comparison

Compare IMUX & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

SELL

Current Price

$7.91

Market Cap

100.2M

Sector

Health Care

ML Signal

SELL

Logo Vivani Medical Inc. (DE)

VANI

Vivani Medical Inc. (DE)

HOLD

Current Price

$1.04

Market Cap

111.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMUX
VANI
Founded
2016
1998
Country
United States
United States
Employees
66
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.2M
111.0M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
IMUX
VANI
Price
$7.91
$1.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
3
Target Price
★ $43.09
$3.83
AVG Volume (30 Days)
★ 330.0K
157.7K
Earning Date
11-16-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 38.00
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $4,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.51
$0.92
52 Week High
$17.43
$1.66

Technical Indicators

Market Signals
Indicator
IMUX
VANI
Relative Strength Index (RSI) 42.34 32.53
Support Level $6.35 $0.92
Resistance Level $8.60 $1.12
Average True Range (ATR) 0.57 0.06
MACD 0.22 -0.00
Stochastic Oscillator 61.97 12.50

Price Performance

Historical Comparison
IMUX
VANI

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

About VANI Vivani Medical Inc. (DE)

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

Share on Social Networks: